Heather Strong1,2, Monica J Mitchell1,2, Alana Goldstein-Leever3,4, Lisa Shook5, Punam Malik6, Lori E Crosby7,8. 1. Department of Psychology, University of Cincinnati, Cincinnati, OH, USA. 2. Division of Behavioral Medicine and Clinical Psychology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA. 3. Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA. 4. Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Sandy Spring, GA, USA. 5. Division of Hematology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA. 6. Division of Experimental Hematology and Cancer Biology-Molecular Genetics, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA. 7. Department of Psychology, University of Cincinnati, Cincinnati, OH, USA. lori.crosby@cchmc.org. 8. Division of Behavioral Medicine and Clinical Psychology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA. lori.crosby@cchmc.org.
Abstract
INTRODUCTION: Sickle cell disease (SCD) is a chronic genetic disease with high morbidity and early mortality; it affects nearly 100,000 individuals in the USA. Bone marrow transplantation, the only curative treatment, is available to less than 20% of patients because of a number of access barriers. Gene transfer therapy (GTT) has been shown to be curative in animal models and is approved for use in humans for early-phase studies at a few centers. GTT would offer a more accessible treatment option available to all patients. It is important to understand patient perspectives on GTT to help ensure human clinical trial success. METHODS: Two focus groups were conducted with younger (18-30 years) and older (31 years and older) adults with SCD to obtain data on patient knowledge and beliefs about GTT. Data from these two focus groups was used to develop a GTT educational brochure. A third focus group was conducted to obtain participant feedback on acceptability and feasibility of education and the brochure. RESULTS: Most adults, especially young adults, had little knowledge about GTT and expressed fear and uncertainty about the side effects of chemotherapy (e.g., hair loss, infertility), use of a human immunodeficiency virus (HIV)-derived viral vector, and potential for cancer risk. Participants wanted full transparency in educational materials, but advised researchers not to share the vector's relation to HIV because of cultural stigma and no HIV virus is used for the GTT vector. CONCLUSION: Older adults had more desire to participate in human clinical GTT trials than younger participants. When recruiting for trials, researchers should develop GTT educational materials that address participant lack of trust in the healthcare system, cultural beliefs, fears related to side effects, and include visual illustrations. Use of such materials will provide adults with SCD the information they need to fully evaluate GTT.
INTRODUCTION: Sickle cell disease (SCD) is a chronic genetic disease with high morbidity and early mortality; it affects nearly 100,000 individuals in the USA. Bone marrow transplantation, the only curative treatment, is available to less than 20% of patients because of a number of access barriers. Gene transfer therapy (GTT) has been shown to be curative in animal models and is approved for use in humans for early-phase studies at a few centers. GTT would offer a more accessible treatment option available to all patients. It is important to understand patient perspectives on GTT to help ensure human clinical trial success. METHODS: Two focus groups were conducted with younger (18-30 years) and older (31 years and older) adults with SCD to obtain data on patient knowledge and beliefs about GTT. Data from these two focus groups was used to develop a GTT educational brochure. A third focus group was conducted to obtain participant feedback on acceptability and feasibility of education and the brochure. RESULTS: Most adults, especially young adults, had little knowledge about GTT and expressed fear and uncertainty about the side effects of chemotherapy (e.g., hair loss, infertility), use of a human immunodeficiency virus (HIV)-derived viral vector, and potential for cancer risk. Participants wanted full transparency in educational materials, but advised researchers not to share the vector's relation to HIV because of cultural stigma and no HIV virus is used for the GTT vector. CONCLUSION: Older adults had more desire to participate in human clinical GTT trials than younger participants. When recruiting for trials, researchers should develop GTT educational materials that address participant lack of trust in the healthcare system, cultural beliefs, fears related to side effects, and include visual illustrations. Use of such materials will provide adults with SCD the information they need to fully evaluate GTT.
Authors: Mari H Dallas; Brandon Triplett; David R Shook; Christine Hartford; Ashok Srinivasan; Joseph Laver; Russell Ware; Wing Leung Journal: Biol Blood Marrow Transplant Date: 2013-02-14 Impact factor: 5.742
Authors: Marlene H Peters-Lawrence; Margaret C Bell; Lewis L Hsu; Ifeyinwa Osunkwo; Phillip Seaman; Miren Blackwood; Edouard Guillaume; Rita Bellevue; Lakshmanan Krishnamurti; Wally R Smith; Carlton D Dampier; Caterina P Minniti Journal: Contemp Clin Trials Date: 2011-12-02 Impact factor: 2.226
Authors: Barbara P Yawn; George R Buchanan; Araba N Afenyi-Annan; Samir K Ballas; Kathryn L Hassell; Andra H James; Lanetta Jordan; Sophie M Lanzkron; Richard Lottenberg; William J Savage; Paula J Tanabe; Russell E Ware; M Hassan Murad; Jonathan C Goldsmith; Eduardo Ortiz; Robinson Fulwood; Ann Horton; Joylene John-Sowah Journal: JAMA Date: 2014-09-10 Impact factor: 56.272
Authors: Karine Dubé; Jane Simoni; Michael Louella; Laurie Sylla; Zahra H Mohamed; Hursch Patel; Stuart Luter; Ann C Collier Journal: AIDS Res Hum Retroviruses Date: 2019-05-21 Impact factor: 2.205
Authors: C Byrnes; M Botello-Harbaum; T Clemons; L Bailey; K M Valdes; V H Coleman-Cowger Journal: J Natl Med Assoc Date: 2022-01-31 Impact factor: 1.798
Authors: Olalekan Lee Aiyegbusi; Karen Macpherson; Lauren Elston; Susan Myles; Jennifer Washington; Nisha Sungum; Mark Briggs; Philip N Newsome; Melanie J Calvert Journal: Nat Commun Date: 2020-12-08 Impact factor: 14.919